Avoid This Pharma Stock

Editor's note: This article is a stock pitch made by a member on CAPS, The Motley Fool's free investing community. The pitch is published unedited and is the opinion of the CAPS member whose pitch it is, in this case: zzlangerhans.

Each week I cull a top stock idea from the pitches made on CAPS, the Motley Fool's 180,000-member free investing community. Want your idea considered for this series? Make a compelling pitch on CAPS with a minimum length of 400 words. Want to follow the weekly picks? Follow me on Facebook or Twitter.

Company

AP Pharma (NASDAQOTCBB: APPAD  )

Star Rating (out of 5)

*

Industry

Health care

Market Cap

$177 million

 

AP Pharma Underperform Pick

Submitted By

zzlangerhans

Member Rating

99.66

Submitted On

3/26/2013

Stock Price At Underperform Recommendation

$0.63

Sources: S&P Capital IQ, Yahoo! Finance, and Motley Fool CAPS.

This Week's Pitch:

I've watched from the sidelines as AP Pharma stock ran and sagged ahead of the APF530 PDUFA, likely the result of a self-fulfilling prophecy of the "run-up" enthusiasts. As always, it is good to be an early adopter of manufactured momentum plays in low float stocks and painful to be late to the party. Getting back to fundamentals, I see AP as a prime candidate for a post-PDUFA decline regardless of outcome. In my mind, the company's goose was cooked when results of the phase III trial indicated that APF530 was equivalent but not superior to the standard of care Aloxi. The smart money abandoned the stock and the next few years were a blur of CRL, time and resource-consuming studies, and dilution. The penny stock share price masks a startling 193M market cap, the result of a massive dilution last July that suggests the company is already looking ahead to their next act after APF530. Even if approved, APF530 is unlikely to become a significant player in the generic-dominated CINV market.

While you can certainly make huge gains in biotech and pharmaceuticals, the best investing approach is to choose great companies and stick with them for the long term. The Motley Fool's free report "3 Stocks That Will Help You Retire Rich" names stocks that could help you build long-term wealth and retire well, along with some winning wealth-building strategies that every investor should be aware of. Click here now to keep reading.


Read/Post Comments (3) | Recommend This Article (2)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On March 28, 2013, at 11:55 AM, 13CROSSBONES wrote:

    You sir, are called for "piling on". APF350 will be a superior way to stop chemotherapy nausea when, not if, it hits the market. While it was disappointing to have a delay involved in bringing AAP350 to market, it will happen and become a preferred method, because it is less repetitive. I fail to see where you deserve an article here at Motley Fool, given your narrow vision.

  • Report this Comment On March 28, 2013, at 12:00 PM, 13CROSSBONES wrote:

    "less repititive and works as well". I am now wondering about the integrity of the FDA, after failing two drugs that work, because of percieved deficiencies. The other is $DVAX's Hepislav.

  • Report this Comment On March 28, 2013, at 12:13 PM, 13CROSSBONES wrote:

    Furthermore, it appears that you wrote this article after hearing the rejection news, though your verbage appears to be predictive.

Add your comment.

DocumentId: 2336282, ~/Articles/ArticleHandler.aspx, 4/16/2014 3:51:38 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement